Previous 10 | Next 10 |
Aerpio Pharmaceuticals (ARPO) announces that razuprotafib met the primary efficacy endpoint at Day 28 with the twice-daily dose group in pen angle glaucoma.The change from baseline in diurnal mean IOP at Day 28 of study eyes treated with razuprotafib BID plus latanoprost showed a st...
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials CINCINNATI, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.(Aerpio) (Nasdaq:...
Intec Pharma (NTEC) +111% after research pact with UK-based GW Pharma.Recon Technology (RCON) +102%.Francesca's Holdings (FRAN) +99% after receiving court approval of first day motions to support ongoing operations.ZW Data Action Technologies (CNET) +101% after opening its firs...
Penny Stocks to Watch For the Second Week of December With December well underway, there is a long list of penny stocks to watch. When investing in penny stocks , we have to consider the various factors that make companies go up or down in value. All investors should ask themsel...
These Biotech Penny Stocks Continue Seeing Positive Sentiment As the latest news suggests, rising Covid cases means more attention is being paid to biotech penny stocks . These low priced stocks have become some of the most intriguing investments during the year. While they can be q...
Looking For Small Cap Stocks To Buy Now? The broader markets are choppy but small cap stocks continue captivating investor interest on Wednesday. But don’t let the lighter trading fool you. With the latest news on Pfizer’s ( PFE Stock Report ) and BioNTech’s...
Aerpio Pharmaceuticals, Inc. (ARPO) Q3 2020 Earnings Conference Call November 10, 2020 08:30 AM ET Company Participants Gina Marek - Vice President, Finance Joseph Gardner - President & Founder Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Julian Harrison - BTIG Pre...
Aerpio Pharms (ARPO): Q3 GAAP EPS of -$0.12 beats by $0.02.Cash and cash equivalents of $47.3MPress Release For further details see: Aerpio Pharms EPS beats by $0.02
Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021 Initiated second clinical trial to evaluate razuprotafib for the prevention and treatment o...
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the C...
News, Short Squeeze, Breakout and More Instantly...
Aerpio Pharmaceuticals Inc. Company Name:
ARPO Stock Symbol:
NASDAQ Market:
Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021 under ticker symbol “AADI” Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and in...
3 Penny Stocks That Investors Are Eyeing Right Now With 2021 moving faster than ever, investors continue to look for the best penny stocks to buy. Although it can be challenging given the current market conditions, there are plenty of ways to find value with penny stocks . The m...